AllSci News
Boehringer Ingelheim's survodutide achieves 16.6% weight loss in Phase III obesity trial
Boehringer Ingelheim reported that survodutide, its investigational glucagon/GLP-1 dual agonist, produced an average body weight reduction of 16.6% over 76...
Zealand Pharma and Roche advance petrelintide into Phase III for chronic weight management
Zealand Pharma (Nasdaq: ZEAL) and Roche announced they will advance petrelintide into Phase 3 development for chronic weight management following Phase 2...
Germany-based mbiomics completes Series A third closing at EUR 30m for microbiome therapeutics
Munich-based mbiomics GmbH has completed a third closing of its Series A round, bringing total financing to EUR 30 million. The latest tranche added EUR 12...
Coultreon Biopharma raises USD 125m Series A to advance oral SIK3 inhibitor
Leuven-based Coultreon Biopharma, formerly known as Onco3R Therapeutics, has closed a USD 125 million Series A financing round to advance its immunology...
Lighthouse Pharmaceuticals closes USD 12m Series A for Alzheimer's drug trial
Novato, California-based Lighthouse Pharmaceuticals, a clinical-stage biopharmaceutical company focused on small-molecule therapies for neurodegenerative...
Chiesi Group acquires KalVista for USD 1.9b, expanding rare disease portfolio with Ekterly
Italy-based Chiesi Group has agreed to acquire Framingham, Massachusetts-based KalVista Pharmaceuticals (Nasdaq: KALV) for USD 27.00 per share in cash,...
Sagimet Biosciences raises USD 175m Series A offering for acne therapeutics
Sagimet Biosciences (NASDAQ: SGMT), a clinical-stage biopharmaceutical company based in San Mateo, California focused on therapeutics targeting...
Fathom Therapeutics raises USD 47m in Series A for AI-enabled small molecule drug design
New York-based Fathom Therapeutics, formerly known as Atommap Corp., has closed an oversubscribed USD 47 million Series A financing round to advance its...
OSE secures FDA orphan designation for pegrizeprument in heart transplant rejection prevention
France-based OSE Immunotherapeutics announced receipt of orphan drug designation from the US FDA for pegrizeprument (VEL-101), a pegylated monovalent antibody fragment targeting…
Newron Pharma's evenamide faces FDA enrollment hold after patient death
Newron Pharmaceuticals said the US Food and Drug Administration has placed a clinical hold on new patient enrollment at US sites in its Phase III ENIGMA-TRS...
Vivacta Biotechnology closes USD 50m Series A and A+ funding for CAR-T therapies
Shanghai-based Vivacta Biotechnology (Shanghai) Co., Ltd. has closed combined Series A and Series A+ financing totaling over USD 50 million to advance its...
Teva acquires Emalex Biosciences in USD 900m deal for ecopipam
Teva Pharmaceutical Industries Ltd. (NYSE & TASE: TEVA) has agreed to acquire Chicago-based Emalex Biosciences for USD 700 million upfront, plus up to USD...
EC approves Henlius and Organon’s Poherdy biosimilar for HER2-positive breast cancer
Shanghai Henlius Biotech and Organon announced that the European Commission has granted marketing authorization for Poherdy (pertuzumab), making it the first approved…
Juniper Bio and Memorial Sloan Kettering partner on hypoxia imaging agent for oropharyngeal cancer
Juniper Biosciences, the Bridgewater, N.J.-based radiopharmaceutical developer, has entered a strategic licensing agreement with Memorial Sloan Kettering Cancer Center (MSK) to advance…
Pfizer's elranatamab meets Phase III primary endpoint in relapsed or refractory multiple myeloma
Pfizer (NYSE: PFE) reported that elranatamab (Elrexfio) met its primary endpoint in the Phase III MagnetisMM-5 trial, demonstrating a statistically...
The AllSci Brief
Systematic R&D and deal news. Daily.